mRNA vaccine helps woman survive pancreatic cancer with no evidence after 7 years

Researchers have pursued cancer vaccines for decades, and recent advances in mRNA technology have generated excitement among patients, doctors, and investors, northernpublicradio.org reported.

A 72-year-old retired accountant, Gustafson, is living a full life with no evidence of her previously lethal stage II pancreatic cancer, according to aspenpublicradio.org. She hikes, travels, and exercises regularly, showing no signs of the disease that was expected to be fatal.

Seven years ago, she became the first person to receive a personalized mRNA vaccine designed to treat pancreatic cancer. This vaccine was created using samples of her tumor to train her immune cells to recognize and attack cancerous cells.

The year has seen progress in mRNA cancer vaccines, with drugmakers Merck and Moderna reporting a 42% reduction in skin cancer recurrence and death in a recent trial. These vaccines, developed using mRNA, genomics, and AI, are also being tested for lung, kidney, bladder, and brain cancers.

Despite some trial failures, results like Gustafson's offer hope. She received nine doses of the vaccine alongside surgery and chemotherapy and credits her daughters for helping her join the trial.

Gustafson said she accepted the trial because of the low survival odds with conventional treatments and was glad to have hope, northernpublicradio.org noted.